Published in Cancer Treat Rep on April 13, 1981
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. J Clin Oncol (1991) 4.22
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res (1999) 4.17
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 3.69
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 3.23
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med (1983) 2.63
Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature (1995) 2.54
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol (1993) 2.40
Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 2.29
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ (1991) 2.20
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Cancer of the breast: the past decade (first of two parts). N Engl J Med (1980) 2.14
Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res (2000) 2.06
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys (1992) 2.05
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A (1989) 2.05
Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue. J Biol Chem (1994) 2.04
Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol (1991) 2.03
Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol (1997) 2.02
Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol (1988) 1.95
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol (1986) 1.94
In-person vs telephone-administered multiple-pass 24-hour recalls in women: validation with doubly labeled water. J Am Diet Assoc (2000) 1.93
Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res (1979) 1.93
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns]. Science (1998) 1.86
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res (1980) 1.78
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am (2006) 1.70
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res (1980) 1.66
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med (1975) 1.65
Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med (1971) 1.65
Longitudinal changes in fatness in white children: no effect of childhood energy expenditure. Am J Clin Nutr (1998) 1.64
Influence of body composition on the accuracy of reported energy intake in children. Obes Res (2000) 1.59
A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.59
Spatial and temporal control of gene therapy using ionizing radiation. Nat Med (1995) 1.59
Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med (1989) 1.59
Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem (1980) 1.58
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem (1989) 1.57
Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest (1988) 1.53
Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest (1996) 1.52
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A (1986) 1.51
Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci U S A (1990) 1.50
The cellular biology of the Reed-Sternberg cell. Blood (1994) 1.50
Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther (1998) 1.50
Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet (1975) 1.49
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest (1985) 1.49
A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer (1972) 1.46
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (1983) 1.45
Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med (1972) 1.44
Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res (1989) 1.41
Who should pay for clinical research? J Clin Oncol (1990) 1.41
Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci (1974) 1.40
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med (1972) 1.40
Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer (1977) 1.39
Diaminobenzidine as a myelin stain in semithin plastic sections. Biotech Histochem (1999) 1.38
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood (1997) 1.37
Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci U S A (1987) 1.34
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34
Philadelphia-chromosome-positive preleukaemic state. Lancet (1972) 1.33
The kinetics of 67gallium incorporation into inflammatory lesions: experimental and clinical studies. J Lab Clin Med (1974) 1.33
Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med (1976) 1.33
Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem (1990) 1.32
Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A (1993) 1.32
Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep (1978) 1.31
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Cross-finger pedicle flaps in the hand. J Bone Joint Surg Am (1971) 1.29
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med (1969) 1.29
Developmental changes in energy expenditure and physical activity in children: evidence for a decline in physical activity in girls before puberty. Pediatrics (1998) 1.28
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem (1991) 1.28
Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia. Biochem Pharmacol (1978) 1.26
Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J (1974) 1.26
Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood (1968) 1.26
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (1989) 1.25
Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A (1992) 1.25
Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest (2000) 1.25
Cancer of the breast: the past decade (second of two parts). N Engl J Med (1980) 1.24
Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood (1996) 1.24
Identification of quantitative trait loci affecting reproduction in pigs. J Anim Sci (2001) 1.24
l-asparaginase resistance in human leukemia--asparagine synthetase. Biochem Pharmacol (1969) 1.23
Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Ann Intern Med (1976) 1.22
Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) (1979) 1.21
Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A (1981) 1.20